Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Kenneth Bilchick Added: 2 weeks ago
HRS Congress 2026 — Dr Kenneth Bilchick (UVA Heart & Vascular Center, Charlottesville, VA, US) joins us to discuss findings from a study examining whether the protective effect of glucagon-like peptide-1 (GLP-1) receptor agonists on atrial fibrillation risk operates independently of weight loss and survival.Interview Questions:What is the current understanding of how GLP-1 receptor agonists may… View more
Author(s): Chao Jiang , Zhao Zixu Added: 5 months ago
AHA Scientific Sessions 2025 – Dr Chao Jiang and Dr Zhao Zixu (Beijing Anzhen Hospital, CN) discuss the findings from the DARE-AF (NCT06433479) randomized clinical trial, investigating whether dapagliflozin reduces atrial fibrillation burden following catheter ablation in patients without diabetes or heart failure.This single-center, open-label trial enrolled 200 patients with persistent atrial… View more
Author(s): Riccardo Cappato , Rui Providencia Added: 1 year ago
What updates do ECAS recommend for catheter ablation of atrial fibrillation?In this short interview, Prof Riccardo Cappato (IRCCS Humanitas Research Hospital, Milan, IT) and Prof Rui Providência (St Bartholomew's Hospital, London, UK) discuss new guidelines released by ECAS on catheter ablation for atrial fibrillation (AF). Prof Cappato and Prof Providência explain the need for an updated and… View more
Author(s): Karim Al-Azizi , Devi Nair , Added: 1 week ago
In this expert discussion, DrKarim Al-Azizi(Baylor Scott & White The Heart Hospital, US), Editor-in-Chief of the Transcatheter Academy, is joined by steering committee members DrDevi Nair(Chief VP of Research, Arkansas Heart Hospital, US) and DrMegan Coylewright(Essentia Health, US) to unpack the landmark CHAMPION-AF trial (NCT05964200) and its implications for stroke prevention in atrial… View more
Author(s): Renato D Lopes Added: 1 year ago
ESC Congress 24 — AF screening with a wearable ECG device increases diagnosis by over 50% but did not significantly reduce hospitalisation rates for stroke.We are joined onsite at ESC Congress 2024 by Dr Renato Lopes (Duke University Medical Center, NC) to discuss the findings from the GUARD-AF Trial (NCT04126486, Bristol-Myers Squibb), which was designed to determine if screening for undiagnosed… View more